Tenet Healthcare Raises 2026 EPS Guidance at 12.9x Forward Earnings
Tenet Healthcare raised its 2026 adjusted EPS guidance, driving multiple broker estimate upgrades, though the gap between trailing and forward earnings metrics raises questions about whether the rally
Tenet Healthcare Raises 2026 EPS Guidance at 12.9x Forward Earnings
NEW YORK, August 15 —
Tenet Healthcare Corporation (THC) raised its 2026 adjusted EPS guidance, spurring multiple broker upgrades at a stock trading 12.9x forward earnings.
- Guidance raised: 2026 adjusted EPS revised upward, specific magnitude undisclosed; multiple Zacks-tracked brokers lifted estimates in unison following the update
- Valuation tension: trailing EPS of $25.88 at $267.9 per share implies roughly 10.3x trailing P/E; the fwd P/E expanding to 12.9x signals the market expects earnings compression ahead, not growth
- Next catalyst: Q3 earnings, where actual adjusted EPS against the raised 2026 guidance range will confirm or collapse the bull case
What Actually Happened
When multiple independent brokers lift estimates simultaneously after a corporate update, the revision was not a rounding-error tweak. The hospital operator was already generating real cash before this update: $21.8bn in TTM revenue growing 6.8% YoY, and $2.2bn in FCF, a roughly 10% FCF margin that most large hospital chains cannot sustain. What the guidance revision implies is that revenue growth is dropping to the bottom line rather than being absorbed by labor inflation or capital expenditure. That is the signal the press release buries.
Hospital operators that print 10% FCF margins and still trade below 13x forward earnings are either genuinely cheap or carrying a risk the market understands and analysts are choosing not to stress. THC forces investors to pick a side on that question.
The Catch
Simply Wall St.'s overvaluation flag looks strange against that fwd P/E, until you map it against trailing EPS of $25.88. At $267.9 per share, the trailing P/E sits near 10.3x. The fwd P/E expanding to that level means forward EPS is priced around $20.77, materially below the trailing figure. Analysts just raised estimates, but from a compressed base. The specific magnitude of the 2026 guidance revision is not publicly disclosed, which leaves the market pricing direction without a destination. Upgrades built on undisclosed guidance are upgrades built on confidence, not math.
Bottom Line
THC is a rare thing in healthcare: an FCF-heavy hospital operator at a value-screen multiple, with a catalyst that just shifted positive. The setup favors investors who can wait for a quarterly print over traders chasing the estimate-revision bounce. The number that changes the thesis in either direction is next quarter's adjusted EPS relative to the $25.88 trailing annual pace. If the run-rate is tracking toward that figure, the overvaluation argument collapses. If it is tracking away from it, Simply Wall St. will have called the ceiling for the right reason.
For a full breakdown of THC's financials and valuation metrics, generate a Basis Report on Tenet Healthcare or model the FCF case through the DCF calculator using the $2.2bn free cash flow base.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Tenet Healthcare raised its 2026 adjusted EPS guidance, prompting multiple brokers to boost earnings estimates.